The U.S. Supreme Court rejected Ranbaxy Laboratories Ltd.'s bid to market a generic version of Pfizer's blockbuster cholesterol drug Lipitor. The Lipitor patent is due to expire in 2010, but currently the drug is Pfizer's biggest moneymaker, bringing in nearly $13 billion last year.

Full Story:
CNNMoney, MarketWatch

Related Summaries